The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA. 2.86
Under pressure from neutralising antibodies induced by vaccination or infection the SARS-
CoV-2 spike gene has become a hotspot for evolutionary change, leading to the failure of all …
CoV-2 spike gene has become a hotspot for evolutionary change, leading to the failure of all …
Monoclonal antibodies lock down SARS-CoV-2 spike
HC Huang, D Angeletti - Trends in Immunology, 2023 - cell.com
SARS-CoV-2 rapidly accumulated mutations in its immunodominant receptor-binding
domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective …
domain (RBD), rendering all clinically authorized monoclonal antibodies (mAbs) ineffective …
Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys
C Fenwick, P Turelli, Y Duhoo, K Lau, C Herate… - Journal of Infection, 2023 - Elsevier
Objectives Due to the rapid evolution of SARS-CoV-2 to variants with reduced sensitivity to
vaccine-induced humoral immunity and the near complete loss of protective efficacy of …
vaccine-induced humoral immunity and the near complete loss of protective efficacy of …
[HTML][HTML] Evolving spike-protein N-glycosylation in SARS-CoV-2 variants
Abstract Since> 3 years, SARS-CoV-2 has plunged humans into a colossal pandemic.
Henceforth, multiple waves of infection have swept through the human population, led by …
Henceforth, multiple waves of infection have swept through the human population, led by …
Understanding the Molecular Actions of Spike Glycoprotein in SARS-CoV-2 and Issues of a Novel Therapeutic Strategy for the COVID-19 Vaccine
Y Matsuzaka, R Yashiro - BioMedInformatics, 2024 - mdpi.com
In vaccine development, many use the spike protein (S protein), which has multiple “spike-
like” structures protruding from the spherical structure of the coronavirus, as an antigen …
like” structures protruding from the spherical structure of the coronavirus, as an antigen …
[HTML][HTML] Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern
The ongoing emergence of SARS-CoV-2 variants of concern (VOCs) that reduce the
effectiveness of antibody therapeutics necessitates development of next-generation …
effectiveness of antibody therapeutics necessitates development of next-generation …
A generalized framework to identify SARS-CoV-2 broadly neutralizing antibodies
Monoclonal antibodies (mAbs) targeting the SARS-CoV-2 receptor-binding domain (RBD)
showed high efficacy in the prevention and treatment of COVID-19. However, the rapid …
showed high efficacy in the prevention and treatment of COVID-19. However, the rapid …
Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN. 1 sublineages
The recently dominant SARS-CoV-2 Omicron JN. 1 has evolved into multiple sublineages,
with recurrent spike mutations R346T, F456L, and T572I, some of which exhibit growth …
with recurrent spike mutations R346T, F456L, and T572I, some of which exhibit growth …
Antigen binding molecules targeting SARS-CoV-2
F Borriello, AH Ramos - US Patent 11,993,644, 2024 - Google Patents
BNMFQWUHWYJTRI-BQFCYCMXSA-N 7-chloro-N-[(2S)-1-[[(1S)-1-cyano-2-[(3S)-2-
oxopiperidin-3-yl] ethyl] amino]-3-cyclopropyl-1-oxopropan-2-yl]-1H-indole-2-carboxamide …
oxopiperidin-3-yl] ethyl] amino]-3-cyclopropyl-1-oxopropan-2-yl]-1H-indole-2-carboxamide …
Antigen binding molecules targeting SARS-CoV-2
G Grigoryan, J Ingraham - US Patent 11,987,616, 2024 - Google Patents
The invention provides, in various embodiments, polypeptides (eg, camelid antibodies and
antigen binding fragments thereof) that specifically bind to Spike glycoprotein of severe …
antigen binding fragments thereof) that specifically bind to Spike glycoprotein of severe …